Patents
Literature
Patsnap Copilot is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
Patsnap Copilot

234 results about "Adenosine diphosphate" patented technology

Adenosine diphosphate (ADP), also known as adenosine pyrophosphate (APP), is an important organic compound in metabolism and is essential to the flow of energy in living cells. ADP consists of three important structural components: a sugar backbone attached to adenine and two phosphate groups bonded to the 5 carbon atom of ribose. The diphosphate group of ADP is attached to the 5’ carbon of the sugar backbone, while the adenosine attaches to the 1’ carbon.

Medical prosthetic devices and implants having improved biocompatibility

A medical prosthetic device or medical implant containing a metal material (A) selected from the group consisting of titanium or an alloy thereof, zirconium or an alloy thereof, tantalum or an alloy thereof, hafnium or an alloy thereof, niobium or an alloy thereof and a chromium-vanadium alloy, wherein surface parts of the metal material (A) are coated with a layer of a corresponding hydride material (B) selected from titanium hydride, zirconium hydride, tantalum hydride, hafnium hydride, niobium hydride and chromium and/or vanadium hydride, respectively, said device or implant being characterised in that the layer of hydride material (B) comprises one or more biomolecule substances (C) associated therewith. The device or implant exhibits improved biocompatibility. The metal material (A) is preferably titanium. The biomolecule substance (C) may be selected from the following types of substances: Natural or recombinant bio-adhesives; natural or recombinant cell attachment factors; natural, recombinant or synthetic biopolymers; natural or recombinant blood proteins; natural or recombinant enzymes; natural or recombinant extracellular matrix proteins; natural or synthetic extracellular matrix biomolecules; natural or recombinant growth factors and hormones; natural, recombinant or synthetic peptide hormones; natural, recombinant or synthetic deoxyribonucleic acids; natural, recombinant or synthetic ribonucleic acids; natural or recombinant receptors; enzyme inhibitors; drugs; biologically active anions and cations; vitamins; adenosine monophosphate (AMP), adenosine diphosphate (ADP) or adenosine triphosphate (A TP); marker biomolecules; amino acids; fatty acids; nucleotides (RNA and DNA bases); and sugars.
Owner:NUMERICAL TECH INC

Fluorescent probe for selectively identifying ATP based on aggregation-induced fluorescence enhancement characteristic, synthetic method and application thereof

ActiveCN106814057AOvercoming easy bleachingOvercoming detectionFluorescence/phosphorescenceHigh concentrationATP Hydrolase
The invention discloses a fluorescent probe for selectively identifying ATP (adenosine triphosphate) based on an aggregation-induced fluorescence enhancement characteristic, a synthetic method and an application thereof. The fluorescent probe 1 is synthesized by taking a benzophenone derivative as a starting material. The invention carries out a detection research on ATP, ADP (adenosine diphosphate), AMP (adenosine monophosphate) and pyrophosphoric acid (PPi) with the fluorescent probe 1, and discoveries that the fluorescent probe has very good sensitivity and selectivity to ATP; compared with the prior art, the invention has the advantages that the synthetic raw material is easy to obtain, the fluorescent probe has high fluorescence quantum yield and strong photobleaching resistance, and the like, and avoids the defect that a conventional fluorescent dye is not suitable for detection under a high concentration; in addition, the fluorescent probe 1 is successfully used for monitoring a reaction process of ATP hydrolase Apyrase in a solution, and is also used for imaging research of ATP in cells. Therefore, the fluorescent probe 1 has a great application prospect in the aspect of detecting the content of in vivo ATP.
Owner:GANNAN NORMAL UNIV

Enzyme preparation for preparing uridylic acid and method for preparing uridylic acid through enzyme catalysis

The invention relates to an enzyme preparation for preparing uridylic acid and a method for preparing the uridylic acid through enzyme catalysis. The method comprises the following steps: taking a material liquid containing uridine as a substrate, adding an escherichia coli cell crushing liquid with activity of uridine kinase and poly-phosphokinase, sodium hexametaphosphate, magnesium sulfate anda small amount of ATP (Adenosintriphosphat), and carrying out an enzymatic reaction under conditions that the pH value is 8.0 and the temperature is 30 DEG C to synthesize the uridylic acid. In a coupling catalysis reaction system, the uridine and the ATP are catalyzed by the uridine kinase to generate the uridylic acid, and ADP (Adenosine Diphosphate) is formed along with the dephosphorylation ofthe ATP. Poly-phosphokinase is in charge of catalyzing the sodium hexametaphosphate and the ADP to generate the ATP, so that the regeneration of the ATP is achieved in reactions. The uridylic acid production method provided by the invention has the advantages of being low in raw material price, short in period, simple and convenient to operate, green and environmentally-friendly and high in yield, and has good industrial application value.
Owner:TIANJIN UNIV OF SCI & TECH

Detection method of poly(adenosine diphosphate-ribose) polymerase

InactiveCN105606671AEnable label-free detectionSimple methodMaterial electrochemical variablesSignalling moleculesPolyadenosine diphosphate ribose polymerase
The invention belongs to the technical field of analytical chemistry and relates to a detection method and application of PARP [poly(adenosine diphosphate-ribose) polymerase]. The detection method mainly includes: modifying a single-stranded DNA (c-kit-1) capable of specifically binding with the PARP on the surface of a gold electrode in a classical mercapto self-assembly mode and enabling c-kit-1 to form a tetramer configuration through treatment; after the tetramer configuration is incubated with the PARP, adding a specific catalytic substrate, namely NAD (nicotinamide ademinedinucleotide) of the PARP, to enable the PARP to self-catalyze to produce PAR with high negative charges; using the negative charges of the PAR for adsorbing electrical signal molecules RuHex with positive charges, quantifying the RuHex adsorbed on the surface of the electrode through an electroanalysis method, and drawing a standard curve according to a relation between electrochemical signals and PARP concentration so as to achieve sensitive PARP detection by measuring the electrochemical signals of to-be-detected samples and calculating. The detection method is high in repeatability and sensitivity and can be applied to detection of the PARP and an inhibitor 3-AB (3-aminobenzamide) thereof.
Owner:NANJING AGRICULTURAL UNIVERSITY

Ligustrazine-butyphthalide combination compound, preparation method of ligustrazine-butyphthalide combination compound, and application of ligustrazine-butyphthalide combination compound to pharmaceuticals

The invention discloses a ligustrazine-butyphthalide combination compound, a preparation method of the ligustrazine-butyphthalide combination compound and an application of the ligustrazine-butyphthalide combination compound to pharmaceuticals. The ligustrazine-butyphthalide combination compound has the following structural formula I as in the description. The phthalic anhydride and the ligustrazine are taken as starting materials, bromization, nucleophilic addition, catalytic dehydration, ester hydrolysis, reduction and esterification reactions are conduced to prepare the ligustrazine-butyphthalide combination compound; a pharmaceutical composition takes the ligustrazine-butyphthalide combination compound as an active pharmaceutical ingredient and is a pharmaceutically acceptable carrier, excipient, diluent, adjuvant, intermedium or a composition. The prepared ligustrazine-butyphthalide combination compound has an excellent effect of inhibiting in-vitro platelet aggregation (ADP) induced platelet aggregation, has a better in-vivo pharmacokinetics properties, and can be used for preventing and treating cardiovascular and cerebrovascular diseases, vascular senile dementia and the complications.
Owner:GUIZHOU MEDICAL UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products